Explore Business Standard
Aurobindo Pharma on Tuesday said it will manufacture and supply the long-acting injectable HIV treatment cabotegravir across 133 countries. The Hyderabad-based drugmaker has been selected as one of the generic manufacturers under the expanded voluntary licensing agreement between the Medicines Patent Pool (MPP) and ViiV Healthcare, the company said in a statement. The agreement allows Aurobindo to manufacture and supply the long-acting injectable HIV treatment across 133 countries, including several low and middle-income markets, it added. This update now includes long-acting cabotegravir (CAB LA) for HIV treatment, in addition to its earlier use for prevention only. The treatment offers an alternative to daily pills, allowing patients to receive just one injection every one or two months. "We are privileged to be part of the sub-license expansion from MPP and ViiV to develop, manufacture, and distribute generic CAB LA in select markets for the treatment of HIV-1, in addition to t
Drug major Cipla is preparing to foray into the weight management segment in India, its MD and global CEO Umang Vohra has said. The Mumbai-based firm is also strengthening its presence in the central nervous system (CNS) therapeutic area, he stated in his address to shareholders in the company's Annual Report for 2024-25. "Our efforts are rooted in understanding patient needs, reducing stigma, and delivering differentiated therapies for niche indications...obesity is emerging as a priority area for Cipla. With a clear strategic intent, we are preparing to enter the weight management segment in India, aiming to address the rising demand for effective obesity solutions," Vohra stated. Several domestic drug firms are developing drugs for weight loss to capitalise on the growing market for obesity and diabetes management. US drugmaker Eli Lilly & Co has already launched its anti-obesity drug Mounjaro in the country. Danish firm Novo Nordisk has also launched its anti-obesity drug ...
Dr Morepen on Tuesday forayed into the growing wellness segment with the launch of a weight management initiative. The company, a fully-owned subsidiary of Morepen Laboratories, is looking to establish itself in the segment which is currently valued at around Rs 12,000 crore and growing at an annual rate of 16 per cent. The company has launched its wellness product -- LightLife -- designed to tackle India's growing obesity crisis. India's obesity rate is increasing and this segment is expected to touch USD 52.3 billion by 2032, "reflecting the urgency to address weight management with solutions that are both safe and effective," Dr Morepen CEO Varun Suri said. With LightLife the company is looking to address the obesity issue without crash diets or harmful fads, he stated. According to the World Obesity Atlas 2024, over 25 per cent of Indian adults are projected to face obesity by 2035. Suri said the company's initiative is about promoting a healthy balanced lifestyle through ...